Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Alex Sirois

Fri, September 4, 2026 at 5:45 PM GMT+3 4 min read

Quick Read

ISRG and SYK each delivered a fifth straight EPS beat, but Intuitive's 85% recurring revenue share creates a compounding moat Stryker can't match.
Intuitive's 11,710 installed da Vinci systems generate daily instrument revenue, backed by 25 upward Wall Street EPS revisions in just 30 days.
Watch the da Vinci 5 upgrade cycle and Stryker's Inari backorder resolution by Q3 as the key inflection points for both stocks.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now. The report is free. Enter your email and see if any of your stocks made the cut.

Intuitive Surgical (NASDAQ: ISRG) and Stryker (NYSE: SYK) both delivered a fifth consecutive EPS beat in Q2 2026. Intuitive rode a fast growing installed base and 36% Ion procedure growth. Stryker fought back from a March cyber incident with 9% organic sales growth. Both raised or narrowed guidance, yet the models diverge in ways that shape long-term returns.

VCG / Getty Images News via Getty Images

Recurring Revenue Carries Intuitive. Capital Backlog Carries Stryker.

Intuitive placed 468 da Vinci systems, including 246 da Vinci 5 units. Instruments and Accessories generated $1.73B, up 18%, and it carries the highest margin in the mix. Non-GAAP gross margin expanded to 70.0%. CEO Dave Rosa said the quarter "reflects the strength of our portfolio". Recurring revenue reached 85% of the total, a quiet compounding engine most investors underestimate.

Stryker delivered $6.59B in revenue, up 9.4%, with adjusted operating margin expanding 170 bps to 27.4%. MedSurg and Neurotechnology grew 9.7%, and Orthopaedics grew 9.1%. Vascular slipped 0.7% because of an Inari plant supply disruption. CEO Kevin Lobo said the team entered the second half "with regained momentum".

Free Report, Just Released

Did Any of Your Stocks Make the Top 10 List?

It is an uncomfortable question, and there is now an answer to it.

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

Open your account and look at what you own. Some of it you bought for a reason you could still defend today. Some of it you bought years ago for a reason you can no longer remember.

The report is free. Put the ten next to what you own and find out which is which.

Enter Your Email and See the Ten →

Free from 24/7 Wall St. It lands in your inbox.

Business Driver

Intuitive Surgical

Stryker

Q2 Revenue Growth

18.5%

9.4%

Recurring Revenue Share

85%

Mixed capital and consumables

Gross Margin

70.0%

66%

AI Deepens One Moat. AI Widens Another's Reach.

Both companies pour resources into artificial intelligence, but the intent differs. Intuitive uses AI to deepen the da Vinci moat. MyIntuitivePlus bundles telepresence, simulation, and AI-driven case insights on da Vinci 5's platform. Rosa outlined "more than 100 planned updates". An extended use instrument program arriving in the first half of 2027 should lower cost per procedure and pull more benign cases onto the system, reinforcing the recurring revenue flywheel.

Stryker uses AI to widen its hospital operating system. The new SmartCare unit merges Vocera and Care AI on a modern cloud stack, and management flagged "really big second half of sales growth". Mako now spans hip, knee, spine, and shoulder across 47 countries, and the handheld Mako RPS is in full US launch. That reflects ecosystem breadth rather than moat depth.

Next Test Cuts Across Robotics and Recovery

I will watch the da Vinci 5 upgrade cycle. Management reminded investors that the SI to XI transition took roughly seven years to peak, so trades will trickle through 2027 and beyond. On Stryker's side, keep an eye on the Inari backorder returning to a manageable level by the end of Q3, plus data from the 1,200-patient Peerless2 trial, which Lobo called "the seminal trial within peripheral vascular".

Why I Lean Toward Intuitive's Quiet Compounding

I lean toward Intuitive for durable compounding. An installed base of 11,710 da Vinci systems feeds instruments and services every single day, and the AI roadmap keeps sharpening switching costs. Wall Street sees the story too: 25 upward EPS revisions in 30 days for FY2026. Stryker still fits investors who want diversified medtech exposure with a cyber recovery kicker. If Mako RPS conversions accelerate and Inari stabilizes, my view could tilt back toward balance. For now, the quiet advantage sits with Intuitive.

Got $1,000? Before You Buy Another Stock, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research point to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the cut -->>

Contact editorial@247wallst.com for any questions or corrections.